Copenhagen, Denmark

ESTRO 2022

Session Item

May 07
14:15 - 15:15
Poster Station 2
06: CNS
Silvia Chiesa, Italy
Poster Discussion
Giant Vestibular Schwannomas – 1 versus 3 fractions?
Lucy Solway, United Kingdom


Giant Vestibular Schwannomas – 1 versus 3 fractions?

Lucy Solway1, Mitchell Hickman2, Sara Meade2, Helen Benghiat2, Hannah Augustus2, Ruth Stange2, Timothy Jackson2, Geoff Heyes2, Peter Monksfield3, Andrew Kay4, Richard Irving3, Swarupsinh Chavda5, Andrew Hartley2, Paul Sanghera2

1University Hospital Birmingham, Oncology, Birmingham, United Kingdom; 2Univeristy Hospital Birmingham, Oncology, Birmingham, United Kingdom; 3Univeristy Hospital Birmingham, ENT, Birmingham, United Kingdom; 4Univeristy Hospital Birmingham, Neurosurgery, Birmingham, United Kingdom; 5Univeristy Hospital Birmingham, Radiology, Birmingham, United Kingdom

Show Affiliations
Purpose or Objective

Stereotactic radiotherapy (SRT) is routinely used to treat Vestibular Schwannomas (VS) to avoid the need for surgical intervention.  It is generally recommended that VS causing brainstem compression are surgically treated.  However, there are some patients who decline surgery or are deemed medically unfit who undergo treatment with SRT.  There is debate amongst clinicians about the best way to treat these large VS and practice varies between 12Gy in 1#, 18Gy in 3# or more prolonged fractionation.

Material and Methods

All patients undergoing CyberKnife Radiotherapy for VS at a regional centre were identified from a prospective database. Treated lesions over 4cc with at least 2 years of follow up were included for this analysis.  All patients were given a key worker contact number to report toxicity events and records from outpatient visits were used to establish toxicity data.  Toxicity was documented for facial and trigeminal nerve via CTCAE v4 grading and timing of occurrence and interventions required to manage symptoms were recorded.  Any other acute or late G3 or 4 toxicity was also recorded.


48 patients were included for analysis treated between 07/2013 and 08/2019.  Treatment volume varied from 4.05-11.61cc (mean 5.66cc).  19 (40%) lesions were treated with 3# and 29 (60%) lesions were treated with 1#. The mean size in the 3 vs. 1# groups was 6.44cc (range 4.06cc-11.61cc) vs. 5.15cc (range 4.05cc-6.67cc) (p=0.0025).In total 7 (15%) patient patients experienced any grade acute facial nerve toxicity, 5 (17%) received 1# with 2 (11%) receiving 3# (p=0.52).  6 of the 7 patients experienced G1 facial twitching alone, 1 patient’s facial nerve function deteriorated to House Brackmann G3 toxicity at 5 months and unfortunately long-term follow up of that patient was not achieved as they died of other causes at 15 months post treatment, they had received 1# treatment. 13 patients experienced any grade acute trigeminal nerve toxicity, 9 (31%) receiving 1# treatment with 4 (21%) receiving 3# (p=0.45).  5 patients had persistent symptoms beyond a year and received medical therapy for management, 3 in the 3# group and 2 in the 1# group.  No patients developed hydrocephalus following SRT.


Despite statistically significantly bigger tumour volumes receiving 3# there were lower rates of acute trigeminal and facial nerve toxicity seen in this series although this did not reach statistical significance.  A randomised trial comparing treatment with 12Gy in 1# vs 18Gy in 3# in VS over 4cc not suitable for surgery or where surgery is declined is warranted.